Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Menstrual Blood Stem Cells for H7N9-Induced Acute Lung Injury
NCT02095444Phase 2Unknown
- Sponsor
- S-Evans Biosciences
- Start
- Mar 2014
- Primary completion
- Jun 2016
- Modality
- Stem Cell Therapies
- Countries
- 1
01
Overview
A Phase 2 trial of menstrual blood-derived mesenchymal stem cells in acute lung injury (ALI), acute respiratory distress syndrome (ARDS), sponsored by S-Evans Biosciences. Status: unknown.
02
Drugs
menstrual blood-derived mesenchymal stem cells
03
Conditions
acute lung injury (ALI)acute respiratory distress syndrome (ARDS)
Beyond the preview
Go deeper on NCT02095444.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02095444.